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Abstract  40 
 41 
Objective: To estimate the magnitude of the correlation between neonatal outcomes of twins and 42 
demonstrate how this information can be used in the design of randomised controlled trials (RCTs) 43 
in women with twin pregnancies. 44 
Design: Secondary analysis of data from 12 RCTs. 45 
Setting: Obstetric care in multiple countries, 2004-2012. 46 
Population or Sample: 4504 twin pairs born to women who participated in RCTs to assess 47 
treatments given during pregnancy. 48 
Methods: Intraclass correlation coefficients (ICCs) were estimated using log binomial and linear 49 
models. 50 
Main Outcome Measures: Perinatal death, respiratory distress syndrome, bronchopulmonary 51 
dysplasia, intraventricular haemorrhage, necrotising enterocolitis, sepsis, neonatal intensive care 52 
unit admission, birthweight, low birthweight and two composite measures of adverse neonatal 53 
outcome. 54 
Results: ICCs for the composite measures of adverse neonatal outcome were all above 0.5, 55 
indicating moderate to strong correlation between adverse outcomes of twins. For individual 56 
neonatal outcomes, median ICCs across trials ranged from 0.13 to 0.79 depending on the outcome. 57 
An example illustrates how ICCs can be used in sample size calculations for RCTs in women with 58 
twin pregnancies. 59 
Conclusions: The correlation between neonatal outcomes of twins varies considerably between 60 
outcomes and may be lower than expected.  Our ICC estimates can be used for designing and 61 
analysing RCTs that recruit women with twin pregnancies and performing meta-analyses that 62 
include such RCTs. Researchers are encouraged to report ICCs for neonatal outcomes in twins in 63 
their own RCTs. 64 
Funding: Australian National Health and Medical Research Council (ID 1052388). 65 
Keywords: Sample size, power, Bayesian analysis, meta-analysis, twins, intraclass correlation 66 
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 68 
Tweetable Abstract 69 
 70 
Correlation between neonatal outcomes of twins depends on the outcome and may be lower than 71 
expected  72 
INTRODUCTION 73 
 74 
Twin births and their associated complications are on the rise. In high income countries, twin births 75 
now account for around 2-4% of all births due to increasing use of assisted reproductive 76 
technologies and advancing maternal age.1 Compared with singleton pregnancies, twins have a 77 
higher risk of adverse neonatal outcomes including preterm birth, respiratory distress syndrome, 78 
low birthweight and mortality.2, 3 Antenatal interventions intended to improve neonatal outcomes, 79 
such as prophylactic progesterone treatment, have been studied specifically in women with twin 80 
pregnancies but with limited success.4-9 Further randomised controlled trials (RCTs) evaluating 81 
promising interventions in this high risk population are needed.  82 
 83 
Designing and analysing RCTs in women with twin pregnancies is challenging. Twins born to the 84 
same mother are expected to have similar or correlated outcomes due to the shared fetal and 85 
neonatal environment and common genetic material. 10, 11  As a result, infants born from the same 86 
twin pregnancy cannot be viewed as two independent trial participants and this has implications 87 
for the trial design and analysis. In particular, the correlation between outcomes of twins should 88 
be taken into account in the sample size calculations to maintain the desired power,12 and in the 89 
analysis to avoid producing results that are over-precise.13   The higher the correlation, the larger 90 
the impact twins have on the sample size and analysis.  91 
 92 
An accurate estimate of the correlation between twins is important, as this is likely to vary across 93 
different outcomes and populations. Higher correlation is expected for certain outcomes, such as 94 
gestational age at birth, where the twin-to-twin delivery interval rarely exceeds one day. Higher 95 
correlation is also expected in certain populations, such as monochorionic twin pregnancies, where 96 
twins share both their genetics and placenta. An estimate of the relevant correlation from an 97 
external source is often required. Since the correlation between neonatal outcomes of twins is 98 
rarely reported in trial publications,14 appropriately designing and analysing RCTs in women with 99 
twin pregnancies can be difficult and published estimates are needed. 100 
 101 
The purpose of this study is to estimate the magnitude of the correlation between neonatal 102 
outcomes of twins for commonly reported outcomes, both overall and by chorionicity. We 103 
demonstrate how this information can be used in sample size calculations for RCTs in women with 104 
twin pregnancies, as this is likely to be their most common use, and discuss other potential uses in 105 






Twelve datasets including a total of 4504 twin pairs were used to estimate ICCs, as summarised in 112 
Appendix Tables S1 and S2. The datasets were from a convenience sample of RCTs chosen based 113 
on the availability of individual participant data for twins with adverse neonatal outcomes defined 114 
in a standardised manner as part of previous studies. The principal investigators of all RCTs were 115 
contacted and provided permission to use the data for the current study. The first dataset comes 116 
from a multicentre, open-label RCT assessing the effectiveness of a cervical pessary compared to 117 
no intervention for preventing poor perinatal outcomes.15 The trial recruited 813 women with a 118 
multiple pregnancy between 12 and 20 weeks’ gestation, of whom 795 had a twin pregnancy (23% 119 
monochorionic, 77% dichorionic) and were part of this study. Exclusion criteria were known 120 
serious congenital defects, fetal death, twin-to-twin transfusion syndrome and known placenta 121 
previa. Women assigned to the cervical pessary group had a pessary inserted between 16 and 20 122 
weeks’ gestation and removed in the 36th week of gestation, while women in the control group 123 
received standard antenatal care. Approximately 55% of women delivered preterm (<37 weeks’ 124 
gestation). 125 
 126 
The remaining datasets come from 11 RCTs included in an individual participant data meta-127 
analysis designed to investigate the effects of progestogens in women with a twin pregnancy.16 128 
Trials were eligible for inclusion if they compared the effect of vaginally administered 129 
progesterone or intramuscular 17-hydroxyprogesterone caproate (17Pc) versus placebo or non-130 
intervention in the second or third trimester in women with a twin pregnancy on either preterm 131 
birth or adverse perinatal outcome. Thirteen trials met the inclusion criteria and contributed 132 
individual participant data to the meta-analysis, however, only the 11 trials that included a 133 
minimum of 40 women with a twin pregnancy were included in this study.4-9, 17-21 134 
Inclusion/exclusion criteria and treatment regimens varied between these trials (Appendix Table 135 
S1). The study size ranged from 67 to 677 twin pairs, with trials either including both 136 
monochorionic and dichorionic twin pregnancies,4, 5, 7, 17, 18, 21 dichorionic twin pregnancies only6, 137 
8, 19 or not recording chorionicity9, 20 (Appendix Table S2). Preterm birth rates (<37 weeks’ 138 
gestation) ranged from 50-79%. 139 
 140 
Neonatal Outcomes 141 
 142 
For each trial, the following 12 neonatal outcomes were defined, where possible: perinatal death 143 
(intrauterine fetal death at any gestational age or neonatal death before hospital discharge); 144 
respiratory distress syndrome (RDS) requiring oxygen for at least 24 hours; bronchopulmonary 145 
dysplasia (BPD); intraventricular haemorrhage (IVH) grade III or IV; necrotising enterocolitis 146 
(NEC) grade II or higher; culture-proven sepsis; admission to the neonatal intensive care unit 147 
(NICU); birthweight; low birthweight (<2500g and <1500g) and two composite measures of 148 
adverse neonatal outcome, as defined in a previous study.16 The first composite outcome included 149 
perinatal death, RDS, BPD, IVH, NEC and sepsis, while the second included perinatal death, RDS, 150 
IVH and NEC.  151 
 152 
Statistical Methods 153 
 154 
The magnitude of the correlation between neonatal outcomes of twins was measured using the 155 
intraclass correlation coefficient (ICC). An ICC of 0 indicates that neonatal outcomes of twins are 156 
completely independent and the ICC approaches 1 for neonatal outcomes typically experienced by 157 
either both or neither members of a twin pair. The data were analysed using log binomial models 158 
for binary outcomes and linear models for continuous outcomes. Adjustment was made for 159 
treatment group, since ICCs calculated ignoring potential treatment effects may be biased,22 and a 160 
single ICC was estimated for both treatment groups combined. Clustering due to twins was taken 161 
into account using generalised estimating equations (GEEs), as this is the most common analysis 162 
approach used to account for twins in RCTs.14, 23 ICCs were estimated by the correlation parameter 163 
for the exchangeable working correlation structure; more complex correlation structures reduce to 164 
an exchangeable correlation structure when the cluster size is two. As a sensitivity analysis, ICCs 165 
were also estimated from linear mixed effects models with a random mother effect. Confidence 166 
intervals (CIs) for ICCs were obtained via bootstrapping using the bias corrected and accelerated 167 
method24 with 2000 bootstrap samples and resampling of clusters (mothers), rather than 168 
individuals (infants). Each trial was analysed separately, both overall and by chorionicity where 169 
available. No analysis was performed for individual outcomes in trials where there were less than 170 
40 sets of twins with available data for the outcome, or less than 10 cases of a binary outcome, as 171 
the ICC estimates were considered too unreliable and GEEs are known to produce biased residuals 172 
when the number of clusters is small.25, 26 ICCs and 95% confidence intervals are presented by 173 
trial, along with the prevalence for binary outcomes and the mean and standard deviation (SD) for 174 
continuous outcomes. ICC estimates are summarised descriptively across trials by the median and 175 
range; no meta-analysis was performed. ICCs were calculated for the components of the composite 176 
outcomes for completeness, however, only summary information is presented for these outcomes 177 
as they are relatively rare and hence are unlikely to be chosen as the primary outcome for a future 178 
trial. Analyses were performed using SAS v9.4 (Cary, NC, USA) based on the %BOOT and 179 




Table 1 and Figure 1 summarise ICC estimates across trials for each of the 12 neonatal outcomes 184 
considered. ICCs were relatively high for the two composite measures of adverse neonatal 185 
outcome, with median (range) values of 0.68 (0.52-0.71) and 0.65 (0.54-0.77) across trials. For 186 
individual neonatal outcomes, median ICCs varied substantially from 0.13 for NEC to 0.79 for 187 
NICU admission and birthweight. The vast majority of individual ICC estimates for each outcome 188 
and trial were above 0.5, indicating a moderate to strong correlation between adverse neonatal 189 
outcomes of twins. ICC estimates were generally fairly consistent across trials, despite 190 
considerable variation in outcome prevalence and differences in inclusion/exclusion criteria 191 
between trials. Chorionicity had no clear effect on ICC estimates, which were mostly similar for 192 
infants from monochorionic and dichorionic twin pregnancies (Appendix Tables S3-S8). Mixed 193 
effects models generally produced similar ICC estimates (Appendix Table S9). 194 
 195 
Example Sample Size Calculation 196 
 197 
To illustrate how the ICCs presented in this article can be used in sample size calculations for 198 
future RCTs in women with twin pregnancies, we present the following hypothetical example. 199 
Suppose a multicentre RCT is planned to assess the effect of a promising new drug for women 200 
with a twin pregnancy on adverse neonatal outcomes. Women with a monochorionic or dichorionic 201 
twin pregnancy diagnosed by ultrasound will be randomised between 16 and 20 weeks’ gestation 202 
to receive the new drug or placebo in the ratio 1:1. The primary outcome for the trial is a composite 203 
neonatal outcome of perinatal death, RDS, BPD, IVH, NEC and sepsis. The outcome prevalence 204 
in the control group is expected to be 15% and the trial investigators believe the new drug will 205 
reduce the prevalence by at least 40%. Two steps are involved in calculating the sample size for 206 
RCTs in women with twin pregnancies. First, the sample size is calculated using standard methods 207 
assuming outcomes of infants from a twin pregnancy are independent. If the proposed trial were 208 
conducted under this assumption, a total of 986 infants (493 per group) would be required to detect 209 
a 40% reduction in the risk of adverse neonatal outcome from 15% to 9%, based on a continuity-210 
corrected chi-square test with two-sided α = 0.05 and 80% power. Second, the sample size is 211 
multiplied by a quantity known as the design effect, which is given by 1+ICC for trials randomising 212 
and treating pregnant women and only including twin pregnancies.28 The ICC estimates presented 213 
in this article can be used to calculate this design effect and hence the final sample size. The median 214 
ICC for the primary outcome of the proposed trial across previous similar trials is 0.68 (Table 1), 215 
which produces a design effect of 1.68 and increases the sample size for the proposed trial to a 216 
total of 1.68×986=1658 twin infants (after rounding up to the next even number), or 829 women 217 
with a twin pregnancy. Power calculations can be performed to examine the impact on power if 218 
the ICC is at the upper end of the range of likely values. For the proposed trial, the sample size of 219 
1658 infants based on an ICC of 0.68 would provide 79% or 75% power if the ICC turned out to 220 
be 0.71 or 0.88 respectively, corresponding to the maximum values for the ICC estimate and the 221 
upper limit of the 95% confidence interval for the ICC estimate observed across similar trials 222 




Main Findings 227 
 228 
We present estimates of the correlation between outcomes of twins for a range of commonly 229 
reported neonatal outcomes using data from 12 RCTs randomising women with twin pregnancies. 230 
ICCs were generally above 0.5, indicating moderate to strong correlation between neonatal 231 
outcomes of twins, and were generally similar by chorionicity. ICCs were also fairly consistent 232 
across trials, despite differences in outcome prevalence and inclusion/exclusion criteria. However, 233 
there was considerable variability in ICCs between outcomes and some ICCs were lower than may 234 
be expected for twins. Our example sample size calculation illustrates how these ICCs can be used 235 
in the design of RCTs in women with twin pregnancies and the large impact that twins can have 236 
on the sample size.  237 
 238 
Strengths and Limitations 239 
 240 
The key strength of this study is that, to our knowledge, it provides the first comprehensive report 241 
of ICCs for neonatal outcomes in twins. These ICCs will inform the design and analysis of future 242 
RCTs and systematic reviews evaluating interventions designed to improve neonatal outcomes in 243 
women with twin pregnancies. Another strength is the use of data from multiple RCTs to provide 244 
multiple estimates of the ICC for each outcome. This provides researchers with a range of likely 245 
ICC values for each neonatal outcome of interest. 246 
 247 
A limitation of this study is that the ICCs were estimated from RCTs chosen for convenience, the 248 
vast majority of which investigated the effect of progestogens on neonatal outcomes, and may not 249 
be representative of all RCTs in women with twin pregnancies. Additional ICC estimates are 250 
needed from other RCTs and epidemiological studies involving twin pregnancies that focus on 251 
different clinical conditions and employ varying inclusion/exclusion criteria to obtain a more 252 
complete picture of the dependence between neonatal outcomes that occurs in twins. A further 253 
limitation is that we did not investigate the degree of outcome concordance within twin pairs that 254 




External estimates of ICCs for neonatal outcomes in twins, such as those presented in this article, 259 
can be used by researchers in several settings. The most common use is likely to be in designing 260 
RCTs in women with twin pregnancies, where it is important to account for the dependence 261 
between neonatal outcomes of twins in sample size calculations to ensure the trial is adequately 262 
powered to answer the primary research question. This can be achieved by simply calculating the 263 
sample size using standard methods assuming outcomes of all infants are independent and then 264 
multiplying by a design effect of 1+ICC.28 Our example sample size calculation illustrates this 265 
process using the median ICC across trials, although in practice it may be sensible to use the ICC 266 
estimate from the most similar trial in terms of inclusion/exclusion criteria. Alternatively, an ICC 267 
estimate may be obtained from a pilot study, although this requires resources that may not be 268 
available and is likely to yield a very imprecise ICC estimate. As our ICC estimates were generally 269 
above 0.5, this indicates that RCTs focusing on twins are likely to require at least 50% more infants 270 
than RCTs focusing on singletons, and that failure to account for twins in the sample size 271 
calculation could result in a trial with much lower than expected power. This does not necessarily 272 
mean that appropriately powered RCTs in twins will be more expensive than trials in singletons, 273 
however, as the costs associated with recruiting mothers and collecting mother level information 274 
are halved for twins. Many RCTs allow women with either a singleton or twin pregnancy to 275 
participate, and our ICC estimates can also be used to calculate the sample size for these trials by 276 
incorporating the twin pregnancy rate in the target population into the calculation of the design 277 
effect.28 278 
 279 
Another likely use of external ICC estimates is in the analysis of RCTs including women with twin 280 
pregnancies. Previous studies have investigated the performance of different statistical methods 281 
for analysing neonatal outcomes in twins and recommended using an approach that takes the 282 
correlation between outcomes of twins into account, such as generalised estimating equations or 283 
mixed effects models.10, 11, 29-32 If a trial is too small or includes too few women with a multiple 284 
pregnancy to provide a precise estimate of the ICC in the analysis, it may be preferable to use an 285 
external estimate. The Bayesian framework provides a formal method of incorporating external 286 
evidence into the analysis by specifying an informative prior for the ICC.33 This has the advantage 287 
of utilising the uncertainty around the ICC estimate as well as the point value, and may be the most 288 
appropriate way to use the external information. 289 
 290 
The final anticipated use of external ICC estimates is in systematic reviews and meta-analyses 291 
involving RCTs that include women with twin pregnancies. Adjustment of standard errors or 292 
sample size is common in meta-analyses of outcomes collected in cluster RCTs34 but this approach 293 
is rarely applied to outcomes of infants from multiple pregnancies. By providing estimates of ICCs 294 
for neonatal outcomes in twins, we hope to encourage researchers to perform similar adjustments 295 
for meta-analyses including RCTs that recruited women with twin pregnancies. Such adjustments 296 
can appropriately increase the uncertainty around the treatment effect estimates and help guard 297 
against overly optimistic conclusions regarding the effectiveness of the intervention.  298 
 299 
As expected, we found considerable variability in ICCs between neonatal outcomes. This 300 
variability may be due to differences in outcome prevalence, as well as the nature of the outcome. 301 
Median ICC estimates were as low as 0.13, which is substantially lower than we had anticipated 302 
for neonatal outcomes of twins. As this median was based on only 2 trials with sufficient data to 303 
estimate the ICC for NEC, this finding should be interpreted with some caution. The next lowest 304 
median ICC estimates observed were 0.36 for IVH and 0.38 for sepsis, which are also somewhat 305 
lower than anticipated. We also expected ICCs to be higher for monochorionic compared to 306 
dichorionic twins due to the shared placenta, however chorionicity had no clear effect on ICC 307 
estimates. This could be due to the relatively small sample sizes available in these subgroups, as 308 
reflected in the wide confidence intervals for the ICCs, or unequal placental sharing in 309 
monochorionic twins. Alternatively, it may be due to the choice of neonatal outcomes studied, 310 
many of which are imprecise measures of the underlying clinical state. Further investigation of the 311 
impact of chorionicity on ICCs using data from larger epidemiological studies would be useful for 312 
informing the design and analysis of future RCTs specifically recruiting women with 313 




The correlation between neonatal outcomes of twins varies considerably between outcomes. It is 318 
generally moderate to high but may be lower than expected for some outcomes. This highlights 319 
the importance of obtaining an accurate estimate of the ICC for the relevant outcome and 320 
population to use in the design and analysis of RCTs that recruit women with twin pregnancies. 321 
Our ICC estimates will be useful to researchers requiring external information on these parameters 322 
for calculating the sample size, performing Bayesian analyses and adjusting meta-analyses to 323 
account for twins. Future RCTs including women with twin pregnancies should make use of these 324 
and other suitable ICC estimates during the trial design phase to ensure they are adequately 325 
powered to answer the primary research question. Researchers are encouraged to report ICCs for 326 
neonatal outcomes in twins in their own trials to add to the growing body of published ICCs. 327 
 328 
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Table 1. Summary of Intraclass Correlation Coefficient Estimates for Neonatal Outcomes Across 487 
Trials 488 
Outcome Median (Range) ICC Trials 
Composite Adverse Neonatal 
Outcome 1a 
0.68 (0.52-0.71) 5-9, 15, 17, 18, 21 
Composite Adverse Neonatal 
Outcome 2b 
0.65 (0.54-0.77) 4-9, 15, 17, 18, 20, 21 
Perinatal Death 0.66 (0.17-0.80) 4, 5, 7, 15, 17, 18, 21 
Respiratory Distress Syndrome 0.65 (0.50-0.74) 4-9, 15, 17, 18, 20, 21 
Bronchopulmonary Dysplasia 0.51 (0.37-0.72) 5, 17, 18 
Intraventricular Haemorrhage 0.36 (0.13-0.45) 4, 5, 17 
Necrotising Enterocolitis 0.13 (0.12-0.14) 15, 18 
Sepsis 0.38 (0.35-0.47) 4, 5, 7, 15, 17, 18 
Admission to Neonatal Intensive 
Care Unit 
0.79 (0.56-0.86) 4-9, 15, 17, 18, 21 
Birthweight 0.79 (0.62-0.85) 4-9, 15, 17-21 
Birthweight <2500g 0.50 (0.37-0.71) 4-9, 15, 17-21 
Birthweight <1500g 0.71 (0.36-0.91) 4-9, 15, 17, 18, 20, 21 
 489 
a Includes perinatal death, respiratory distress syndrome, bronchopulmonary dysplasia, 490 
intraventricular haemorrhage, necrotising enterocolitis and sepsis 491 
b Includes perinatal death, respiratory distress syndrome, intraventricular haemorrhage and 492 
necrotising enterocolitis 493 
Figure 1. Boxplots of intraclass correlation coefficient estimates across trials by outcome. 494 
Abbreviations: COMP, composite adverse neonatal outcome; Death, perinatal death; RDS, 495 
respiratory distress syndrome; BPD, bronchopulmonary dysplasia; IVH, intraventricular 496 
haemorrhage; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; BW, 497 




Table S1. Characteristics of Trials Used to Estimate Intraclass Correlation Coefficients 








Women with a 
multiple pregnancy 12-
20 weeks’ gestation 
Known serious congenital defects, fetal 
death, twin-to-twin transfusion syndrome, 
known placenta previa 
Cervical pessary inserted 
16-20 weeks’ gestation and 
removed in the 36th week of 






    









by ultrasound <16 
weeks' gestation 
Age <18 years, known allergy to 
progesterone or peanuts, history of 
hormone-associated thromboembolic 
disorders, rupture of membranes, treatment 
for signs of twin-to-twin transfusion 
syndrome, intentional fetal reduction, 
known major structural or chromosomal 
fetal abnormality, known or suspected 
malignancy in genitals or breasts, known 
liver disease, higher-order multiple 
pregnancies, women who did not speak 
and understand Danish or German, as 
appropriate 
Vaginal progesterone 
pessaries (200mg) vs 
vaginal placebo pessaries 
self-administered daily from 
20+0-23+6 weeks’ gestation 
until 33+6 weeks’ or 
occurrence of either rupture 
of membranes or delivery 





Women carrying twins 
16+0-20+3 weeks’ 
gestation 
Serious fetal anomalies, spontaneous death 
of a fetus >12 weeks, presumed 
monoamniotic placenta, suspected twin-to-
twin transfusion syndrome, marked 
ultrasonographic growth discordance, 
planned nonstudy progesterone therapy 
>16 weeks, in-place or planned cerclage, 
major uterine anomaly, treatment with 
Weekly intramuscular 
injections of 17Pc (250mg) 
vs placebo starting at 16+0-
20+6 weeks’ gestation and 
continuing until the end of 




10,000 or more units of unfractionated 
heparin per day, treatment with low-
molecular-weight heparin at any dose, 
major chronic medical diseases, twin 
gestations that were the result of 
intentional fetal reduction 





Women with a 
multiple pregnancy 15-




Women with a previous spontaneous 
preterm birth <34 weeks, serious 
congenital defects or death of one or more 
fetuses, early signs of twin-to-twin 
transfusion syndrome, primary cerclage 
Weekly intramuscular 
injections of 17Pc (250mg) 
vs placebo from 16-20 
weeks’ gestation until 36 
weeks’ or delivery 









established by scan 
<20 weeks' gestation, 
and attending the 
antenatal clinic during 
the recruitment period 
Pregnancy complicated by a recognised 
structural or chromosomal fetal 
abnormality at the time of recruitment, 
contraindications to progesterone, planned 
cervical suture, planned elective delivery 
<34 weeks, planned intervention for twin-
to-twin transfusion <22 weeks, higher 
order multiple pregnancy 
Daily progesterone gel 
(90mg) vs placebo self-
administered vaginally for 
10 weeks from 24+0 weeks’ 
gestation 









by ultrasound and 
written informed 
consent 
Singleton pregnancies, monochorionic 
twin pregnancies, triplets or higher order 
multiple pregnancies, elective cervical 
cerclage <14 weeks, history of hepatic 
problems or gestational cholestasis, 
abnormal liver enzymes, abnormal kidney 
function, local allergy to micronised 
natural progesterone, allergy to peanuts, 
recurrent vaginal bleeding, recurrent 
vaginal infections, fetal anomalies 
diagnosed by ultrasound, alcohol or illicit 
Two vaginal progesterone 
pessaries (400mg or 200mg) 
vs placebo self-inserted 
daily at bedtime from 20 
weeks’ gestation until 34 
weeks’ or delivery 
3 
 
drug consumption, smoking ≥10 
cigarettes/day 








maternal age ≥18 
years, recruited at 12-
20 weeks’ gestation 
Ultrasonographically diagnosed fetal 
anomalies, elective cervical cerclage <14 
weeks, hypertension, diabetes mellitus, 
asthma, history of deep vein thrombosis, 
history of hepatic disease or abnormal liver 
enzymes, pre-existing renal disease or 
abnormal kidney function, seizure 
disorders 
Weekly intramuscular 
injections of 17Pc (250mg) 
vs placebo from16-20 
weeks’ gestation until 36 
weeks’ 





Women with a 
dichorionic-diamniotic 
twin pregnancy at 15-
23 weeks’ gestation 
with a detailed 
ultrasound examination 
showing no major fetal 
anomalies 
Age <18 years, taken any progestins >15 
weeks, symptomatic uterine contractions, 
rupture of fetal membranes, 
contraindication to prolonging the 
pregnancy, pre-existing condition that 
might be worsened by progesterone, pre-
existing medical condition carrying a high 
risk of preterm delivery 
Weekly intramuscular 
injections of 17Pc (250mg) 
vs placebo from 16-24 
weeks’ gestation until 34 
weeks’ or delivery 
- Senat9 Multicentre, 
open-label 
RCT 




measured in the 
sagittal plane by 
routine transvaginal 
ultrasound according to 
the standard technique, 
who agreed to regular 
follow-up and provided 
written informed 
consent 
Cervical dilatation >3cm, premature 
rupture of the membranes, placenta previa, 
monochorial monoamniotic pregnancy, 
signs of twin-to-twin transfusion 
syndrome, severe intrauterine growth 
restriction, known major structural or 
chromosomal fetal abnormality, death of 1 
fetus, any maternal or fetal disease 
requiring preterm delivery, progesterone 
therapy before inclusion, ongoing 
anticonvulsant treatment, participation in 
any other treatment trial, twin gestations 
resulting from intentional fetal reduction 
Twice weekly intramuscular 
injections of 17Pc (500mg) 
from 24+0-31+6 weeks’ 
gestation until 36 weeks’ or 
preterm delivery vs no 
treatment  
- Aboulghar19 Single centre, 
placebo-
Healthy pregnant 
women who conceived 
Previous pregnancy, serious fetal 
anomalies for which termination may be 
Vaginal progesterone 





after IVF/ICSI between 
18-24 weeks’ 
gestation, with a first 
pregnancy, singleton or 
dichorionic twins, 
normal uterine and 
cervical anatomy, and 
normal fetal anatomy 
considered, intrauterine growth restriction, 
mono-chorionic and mono-amniotic twins, 
uterine anomalies, triplet pregnancies, 
cervical cerclage 
placebo twice daily from 
randomisation until 37 
weeks’ gestation or onset of 
preterm birth  





Pregnant women with 
two or more live 
fetuses confirmed at 
16-18 week ultrasound, 
16+0-20+6 weeks’ 
gestation 
Placenta previa, pre-existing hypertension, 
known major fetal anomaly detected on 
ultrasound, monoamniotic monozygotic 
multiple pregnancies, maternal seizure 
disorder, active or history of 
thromboembolic disease, maternal liver 
disease, known or suspected breast 
malignancy or pathology, known or 
suspected progesterone-dependent 
neoplasia, plans to move to another city 
during pregnancy, previous participation in 
this trial or other perinatal clinical trials 
during this pregnancy, known sensitivity to 
progesterone 
Daily progesterone gel 
(90mg) vs placebo self-
administered vaginally from 
randomisation until 35+6 
weeks’ gestation 





Women with a twin 
pregnancy, prior 
spontaneous preterm 
birth or uterine 
malformation  
Abortions and deliveries 20-24 weeks, 
prophylactic cervical cerclage 
Vaginal progesterone 
suppositories (100mg) vs 
placebo nightly from 24 





Table S2. Sample Size by Trial and Chorionicity 
Trial Number of Women 
With a Twin Pregnancya 
Number (%) of Women 
with Monochorionic 
Pregnancy 
Number (%) of Women 
with Dichorionic 
Pregnancy 
Number (%) of Women 
with Unknown 
Chorionicity 
Liem 795  181 (22.8) 609 (76.6) 5 (0.6) 
Rode 677 100 (14.8) 577 (85.2) 0 (0.0) 
Rouse 661 103 (15.6) 551 (83.4) 7 (1.1) 
Lim 650 112 (17.2) 538 (82.8) 0 (0.0) 
Norman 500 92 (18.4) 408 (81.6) 0 (0.0) 
Serra 290 0 (0.0) 290 (100.0) 0 (0.0) 
Nassar 286 41 (14.3) 222 (77.6) 23 (8.0) 
Combs 240 0 (0.0) 240 (100.0) 0 (0.0) 
Senat 165 0 (0.0) 0 (0.0) 165 (100.0) 
Aboulghar 92 0 (0.0) 92 (100.0) 0 (0.0) 
Wood 81 0 (0.0) 0 (0.0) 81 (100.0) 
Cetingoz 67 9 (13.4) 26 (38.8) 32 (47.8) 
 
a Some trials included women with single or higher order multiple pregnancies but only women with twin pregnancies were included 




Table S3. Intraclass Correlation Coefficients for Composite Adverse Neonatal Outcome 1d by Trial and Chorionicity 
Trial Prevalence (%) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 9.94 0.68 (0.59, 0.76) 0.62 (0.43, 0.78) 0.73 (0.62, 0.82) 
Rouse 17.70 0.70 (0.62, 0.77) 0.86 (0.70, 0.96) 0.65 (0.56, 0.73) 
Lim 15.25 0.68 (0.59, 0.75) 0.76 (0.56, 0.90) 0.66 (0.57, 0.75) 
Norman 12.09 0.54 (0.43, 0.67) 0.50 (0.23, 0.77) 0.56 (0.41, 0.70) 
Serra 14.66 0.52 (0.38, 0.66) a 0.52 (0.38, 0.66) 
Nassar 22.28 0.68 (0.56, 0.78) 0.86 (0.43, 1.00) 0.68 (0.55, 0.79) 
Combs 14.04 0.71 (0.56, 0.84) a 0.71 (0.56, 0.84) 
Senat 29.93 0.64 (0.49, 0.77) b b 
Cetingoz 17.16 0.65 (0.32, 0.88) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 
c Insufficient data to estimate ICC 
d Includes perinatal death, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, necrotising 




Table S4. Intraclass Correlation Coefficients for Composite Adverse Neonatal Outcome 2d by Trial and Chorionicity 
Trial Prevalence (%) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 8.23 0.65 (0.54, 0.74) 0.63 (0.42, 0.82) 0.66 (0.54, 0.77) 
Rode 11.87 0.77 (0.69, 0.84) 0.82 (0.57, 0.96) 0.76 (0.66, 0.84) 
Rouse 17.08 0.68 (0.60, 0.75) 0.85 (0.69, 0.96) 0.62 (0.52, 0.71) 
Lim 14.10 0.67 (0.59, 0.76) 0.80 (0.56, 0.93) 0.65 (0.55, 0.75) 
Norman 10.85 0.56 (0.44, 0.68) 0.62 (0.31, 0.86) 0.54 (0.40, 0.68) 
Serra 14.31 0.54 (0.40, 0.68) a 0.54 (0.40, 0.68) 
Nassar 20.53 0.67 (0.54, 0.77) 0.94 (0.36, 1.00) 0.64 (0.50, 0.76) 
Combs 14.04 0.71 (0.56, 0.84) a 0.71 (0.56, 0.84) 
Senat 29.22 0.62 (0.46, 0.74) b b 
Wood 20.37 0.65 (0.40, 0.87) b b 
Cetingoz 17.16 0.65 (0.32, 0.88) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 
c Insufficient data to estimate ICC 




Table S5. Intraclass Correlation Coefficients for Admission to Neonatal Intensive Care Unit by Trial and Chorionicity 
Trial Prevalence (%) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 13.05 0.72 (0.64, 0.79) 0.67 (0.51, 0.80) 0.75 (0.66, 0.83) 
Rode 48.82 0.86 (0.81, 0.89) 0.95 (0.85, 1.00) 0.84 (0.79, 0.88) 
Rouse 48.58 0.81 (0.76, 0.85) 0.88 (0.74, 0.96) 0.80 (0.74, 0.85) 
Lim 18.31 0.79 (0.72, 0.85) 0.84 (0.69, 0.94) 0.77 (0.69, 0.84) 
Norman 39.40 0.79 (0.73, 0.84) 0.87 (0.74, 0.96) 0.77 (0.70, 0.83) 
Serra 11.90 0.56 (0.40, 0.71) a 0.56 (0.40, 0.71) 
Nassar 36.89 0.80 (0.72, 0.87) c 0.76 (0.66, 0.84) 
Combs 38.56 0.79 (0.70, 0.86) a 0.79 (0.70, 0.86) 
Senat 41.21 0.85 (0.75, 0.93) b b 
Cetingoz 29.10 0.68 (0.42, 0.86) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 




Table S6. Intraclass Correlation Coefficients for Birthweight by Trial and Chorionicity 
Trial Mean (SD) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 2344 (637) 0.81 (0.77, 0.83) 0.83 (0.76, 0.88) 0.80 (0.75, 0.83) 
Rode 2434 (584) 0.80 (0.76, 0.83) 0.85 (0.77, 0.91) 0.79 (0.74, 0.83) 
Rouse 2259 (617) 0.85 (0.82, 0.87) 0.88 (0.83, 0.93) 0.84 (0.80, 0.86) 
Lim 2362 (683) 0.80 (0.75, 0.84) 0.78 (0.63, 0.88) 0.81 (0.74, 0.85) 
Norman 2325 (619) 0.79 (0.74, 0.83) 0.85 (0.76, 0.91) 0.78 (0.72, 0.82) 
Serra 2350 (508) 0.70 (0.62, 0.77) a 0.70 (0.62, 0.77) 
Nassar 2241 (569) 0.78 (0.71, 0.83) 0.79 (0.62, 0.91) 0.77 (0.69, 0.83) 
Combs 2371 (534) 0.70 (0.60, 0.77) a 0.70 (0.60, 0.77) 
Senat 2145 (534) 0.83 (0.77, 0.88) b b 
Aboulghar 2345 (505) 0.62 (0.46, 0.77) a 0.62 (0.46, 0.77) 
Wood 2291 (559) 0.75 (0.62, 0.86) b b 
Cetingoz 2288 (562) 0.78 (0.59, 0.89) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 




Table S7. Intraclass Correlation Coefficients for Birthweight <2500g by Trial and Chorionicity 
Trial Prevalence (%) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 54.87 0.50 (0.44, 0.56) 0.47 (0.32, 0.60) 0.50 (0.43, 0.57) 
Rode 49.85 0.50 (0.43, 0.57) 0.61 (0.44, 0.78) 0.48 (0.41, 0.55) 
Rouse 61.95 0.61 (0.54, 0.67) 0.58 (0.35, 0.77) 0.60 (0.53, 0.67) 
Lim 51.85 0.52 (0.45, 0.59) 0.48 (0.31, 0.65) 0.53 (0.45, 0.60) 
Norman 56.69 0.48 (0.40, 0.56) 0.41 (0.21, 0.61) 0.49 (0.41, 0.58) 
Serra 57.96 0.47 (0.36, 0.57) a 0.47 (0.36, 0.57) 
Nassar 64.57 0.53 (0.43, 0.64) 0.45 (0.15, 0.72) 0.53 (0.41, 0.66) 
Combs 55.49 0.50 (0.39, 0.62) a 0.50 (0.39, 0.62) 
Senat 74.68 0.55 (0.39, 0.70) b b 
Aboulghar 51.95 0.41 (0.20, 0.61) a 0.41 (0.20, 0.61) 
Wood 56.88 0.37 (0.16, 0.58) b b 
Cetingoz 56.72 0.71 (0.51, 0.88) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 




Table S8. Intraclass Correlation Coefficients for Birthweight <1500g by Trial and Chorionicity 
Trial Prevalence (%) ICC (95% CI) - All 
Twins 
ICC (95% CI) - 
Monochorionic Twins 
ICC (95% CI) - 
Dichorionic Twins 
Liem 9.42 0.75 (0.66, 0.83) 0.71 (0.52, 0.89) 0.76 (0.65, 0.84) 
Rode 6.72 0.78 (0.68, 0.87) 0.44 (-0.03, 0.80) 0.80 (0.68, 0.89) 
Rouse 11.00 0.77 (0.68, 0.85) 0.72 (0.50, 0.88) 0.79 (0.69, 0.87) 
Lim 10.96 0.75 (0.66, 0.82) 0.90 (0.74, 1.00) 0.72 (0.62, 0.81) 
Norman 9.73 0.70 (0.58, 0.80) 0.73 (0.36, 0.93) 0.71 (0.57, 0.83) 
Serra 6.06 0.48 (0.29, 0.72) a 0.48 (0.29, 0.72) 
Nassar 9.89 0.70 (0.51, 0.84) c 0.73 (0.55, 0.87) 
Combs 7.59 0.71 (0.45, 0.87) a 0.71 (0.45, 0.87) 
Senat 14.29 0.70 (0.38, 0.88) b b 
Wood 10.00 0.91 (0.63, 1.00) b b 
Cetingoz 8.21 0.36 (-0.05, 0.92) c c 
 
a Monochorionic twins excluded from trial 
b Chorionicity unknown 




Table S9. Summary of Intraclass Correlation Coefficient Estimates for Neonatal Outcomes from Linear Mixed Effects Models Across 
Trials 
Outcome Median (Range) ICC Trials 
Composite Adverse Neonatal Outcome 1a 0.68 (0.54-0.71) 5-9, 15, 17, 18, 21 
Composite Adverse Neonatal Outcome 2b 0.66 (0.56-0.77) 4-9, 15, 17, 18, 20, 21 
Perinatal Death 0.67 (0.16-0.79) 4, 5, 7, 15, 17, 18, 21 
Respiratory Distress Syndrome 0.65 (0.50-0.74) 4-9, 15, 17, 18, 20, 21 
Bronchopulmonary Dysplasia 0.51 (0.36-0.72) 5, 17, 18 
Intraventricular Haemorrhage 0.37 (0.15-0.46) 4, 5, 17 
Necrotising Enterocolitis 0.14 (0.14-0.15) 15, 18 
Sepsis 0.40 (0.35-0.51) 4, 5, 7, 15, 17, 18 
Admission to Neonatal Intensive Care 
Unit 
0.79 (0.56-0.86) 4-9, 15, 17, 18, 21 
Birthweight 0.78 (0.62-0.85) 4-9, 15, 17-21 
Birthweight <2500g 0.50 (0.37-0.70) 4-9, 15, 17-21 
Birthweight <1500g 0.72 (0.31-0.86) 4-9, 15, 17, 18, 20, 21 
 
a Includes perinatal death, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, necrotising 
enterocolitis and sepsis 
b Includes perinatal death, respiratory distress syndrome, intraventricular haemorrhage and necrotising enterocolitis 
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